Jackson A Gondim1, Lucas Alverne F de Albuquerque2, Joao Paulo Almeida3, Tania Bulcao4, Erika Gomes5, Michele Schops1, Raquel Vasconcelos4, Flora da Paz4, Sergio Botelho Guimarães6. 1. Department of Neurosurgery, Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil. 2. Department of Neurosurgery, Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil. Electronic address: lucasalverne@yahoo.com.br. 3. Division of Neurosurgery, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. 4. Department of Endocrinology, Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil. 5. Department of Ear, Nose and Throat Surgery, Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil. 6. Department of Surgery, Universidade Federal do Ceará, Fortaleza, Ceará, Brazil.
Abstract
OBJECTIVE: Symptomatic pituitary apoplexy is a rare but life-threatening condition caused by sudden hemorrhage or infarction of a pituitary adenoma. In the current study, we aim to evaluate the clinical presentation, management, and clinical outcomes in a cohort of patients who were treated for this condition in our center in the last 16 years. METHODS: We performed a retrospective analysis of all patients who underwent endoscopic endonasal surgery for treatment of symptomatic pituitary apoplexy between 2001 and 2016 in our center. RESULTS: A total of 39 patients were included in the study, mean age of 54.9 years (range, 18-70 years) and mean follow-up 5.1 years (range, 0.6-16 years). Most of the patients had nonfunctioning adenomas (32 patients). Headache (89%), visual impairment (79%), and hypopituitarism (86%) were the most common preoperative findings. Surgical treatment led to gross total resection in 31 patients (79.4%). During follow-up, visual fields and oculomotor improvement was observed in 23 (74.1%) and 21 (67.7%) of the patients, respectively. Intractable headache also improved in all patients. Hypopituitarism was present in 77% of patients after surgery. In this series, no cerebrospinal fluid leak, vascular injury, or infection was observed. There was no postoperative mortality. CONCLUSIONS: The endoscopic endonasal transsphenoidal approach is an effective modality to treat pituitary apoplexy with a high rate of success and minimal risk in selected cases. Although reversion of preoperative visual deficits is often observed, hormonal deficits tend to persist, and require long-term hormonal therapy, even after successful endoscopic endonasal surgical resection.
OBJECTIVE: Symptomatic pituitary apoplexy is a rare but life-threatening condition caused by sudden hemorrhage or infarction of a pituitary adenoma. In the current study, we aim to evaluate the clinical presentation, management, and clinical outcomes in a cohort of patients who were treated for this condition in our center in the last 16 years. METHODS: We performed a retrospective analysis of all patients who underwent endoscopic endonasal surgery for treatment of symptomatic pituitary apoplexy between 2001 and 2016 in our center. RESULTS: A total of 39 patients were included in the study, mean age of 54.9 years (range, 18-70 years) and mean follow-up 5.1 years (range, 0.6-16 years). Most of the patients had nonfunctioning adenomas (32 patients). Headache (89%), visual impairment (79%), and hypopituitarism (86%) were the most common preoperative findings. Surgical treatment led to gross total resection in 31 patients (79.4%). During follow-up, visual fields and oculomotor improvement was observed in 23 (74.1%) and 21 (67.7%) of the patients, respectively. Intractable headache also improved in all patients. Hypopituitarism was present in 77% of patients after surgery. In this series, no cerebrospinal fluid leak, vascular injury, or infection was observed. There was no postoperative mortality. CONCLUSIONS: The endoscopic endonasal transsphenoidal approach is an effective modality to treat pituitary apoplexy with a high rate of success and minimal risk in selected cases. Although reversion of preoperative visual deficits is often observed, hormonal deficits tend to persist, and require long-term hormonal therapy, even after successful endoscopic endonasal surgical resection.
Authors: Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed Journal: J Neurooncol Date: 2021-02-21 Impact factor: 4.130
Authors: Emma M H Slot; Rengin Sabaoglu; Eduard H J Voormolen; Eelco W Hoving; Tristan P C van Doormaal Journal: J Neurol Surg B Skull Base Date: 2021-08-20
Authors: Michael K Ghiam; Darius E Chyou; Cortney L Dable; Andrew P Katz; Daniel G Eichberg; Hang Zhang; Alejandro R Ayala; Atil Y Kargi; Ricardo J Komotar; Zoukaa Sargi Journal: J Neurol Surg B Skull Base Date: 2021-05-25
Authors: Mohamed A R Soliman; Sydney Eaton; Elise Quint; Abdullah F Alkhamees; Saba Shahab; Avalon O'Connor; Erika Haberfellner; Jacob Im; Abdurrahim A Elashaal; Francis Ling; Mustafa Elbreki; Tommy Dang; Dante J Morassutti; Abdalla Shamisa Journal: World Neurosurg Date: 2020-04-13 Impact factor: 2.104